Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (DE:82P)
FRANKFURT:82P
RESEARCH TOOLSreports
Holding DE:82P?
Track your performance easily
See the Price Targets and Ratings of:
82P Analyst Ratings
Moderate Buy
3 Buy
3 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
82P Stock 12 Month Forecast
Average Price Target
€19.74
▲(18.21% Upside)
| Highest Price Target€37.25 | Average Price Target€19.74 | Lowest Price Target€11.46 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Barclays
Reiterated
11/12/24
Truist Financial
Reiterated
11/07/24
Piper Sandler
Reiterated
11/07/24
H.C. Wainwright
Reiterated
11/07/24
Needham
Reiterated
11/07/24
RBC Capital
Reiterated
11/06/24
Jefferies
Assigned
09/24/24
J.P. Morgan
€9.55
Sell
-42.81%
Downside
Downgraded
08/12/24
Sell Rating on Pacira Pharmaceuticals Amid Patent Invalidation and Revenue Risks
Raymond James
―
Hold
―
Downgraded
08/12/24
Raymond James downgrades Pacira Pharmaceuticals (PCRX) to a Hold
Oppenheimer
€54.44
Buy
225.98%
Upside
Reiterated
03/01/24
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (NASDAQ: PHAT) and Pacira Pharmaceuticals (NASDAQ: PCRX)
Best Analysts Covering Pacira Pharmaceuticals
Which Analyst Should I Follow If I Want to Buy DE:82P and Sell After:
1 Month
xxx
Success Rate
17/43 ratings generated profit
Average Return
-0.95%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 39.53% of your transactions generating a profit, with an average return of -0.95% per trade.
3 Months
xxx
Success Rate
18/40 ratings generated profit
Average Return
-0.70%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 45.00% of your transactions generating a profit, with an average return of -0.70% per trade.
1 Year
Success Rate
12/40 ratings generated profit
Average Return
-9.20%
reiterated a buy rating 17 days ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -9.20% per trade.
2 Years
xxx
Success Rate
15/40 ratings generated profit
Average Return
-13.56%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -13.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
82P Analyst Recommendation Trends
Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
11
11
11
2
1
Buy
8
5
5
2
2
Hold
2
7
7
6
4
Sell
0
2
2
3
2
Strong Sell
0
0
0
0
0
total
21
25
25
13
9
Each month's total comprises the sum of three months' worth of ratings.
82P Financial Forecast
82P Stock Forecast FAQ
What is DE:82P’s average 12-month price target, according to analysts?
Based on analyst ratings, Pacira Pharmaceuticals’s 12-month average price target is €19.74.
What is DE:82P’s upside potential, based on the analysts’ average price target?
Pacira Pharmaceuticals has 18.21% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Pacira Pharmaceuticals a Buy, Sell or Hold?
Pacira Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 3 hold ratings and 1 sell ratings.
What is Pacira Pharmaceuticals’s share price target?
The average share price target for Pacira Pharmaceuticals is €19.74. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €37.25 ,and the lowest forecast is €11.46. The average share price target represents 18.21% Increase from the current price of €16.7.
The highest analyst share price target is €37.25 ,and the lowest forecast is €11.46. The average share price target represents 18.21% Increase from the current price of €16.7.
What do analysts say about Pacira Pharmaceuticals?
Pacira Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of Pacira Pharmaceuticals?
To buy shares of DE:82P, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.